vs
Side-by-side financial comparison of PubMatic, Inc. (PUBM) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $62.6M, roughly 2.5× PubMatic, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -20.0%, a 91.2% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -2.0%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $10.7M).
PubMatic, Inc. develops and implements online advertising software and strategies for the digital publishing and advertising industry. PubMatic's sell-side, real-time programmatic ad transaction advertising software puts publishers of websites, videos, and mobile apps into contact with ad buyers by using automated systems, while allowing users to opt-out of having their personal information collected on internet searches. PubMatic has a number of offices in countries around the world.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
PUBM vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.6M | $158.6M |
| Net Profit | $-12.5M | $112.9M |
| Gross Margin | 58.3% | — |
| Operating Margin | 17.3% | 70.2% |
| Net Margin | -20.0% | 71.2% |
| Revenue YoY | -2.0% | 3661.1% |
| Net Profit YoY | -31.9% | 528.0% |
| EPS (diluted) | $-0.27 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $62.6M | — | ||
| Q4 25 | $80.0M | — | ||
| Q3 25 | $68.0M | — | ||
| Q2 25 | $71.1M | — | ||
| Q1 25 | $63.8M | $158.6M | ||
| Q4 24 | $85.5M | $22.6M | ||
| Q3 24 | $71.8M | — | ||
| Q2 24 | $67.3M | — |
| Q1 26 | $-12.5M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-6.5M | — | ||
| Q2 25 | $-5.2M | — | ||
| Q1 25 | $-9.5M | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q3 24 | $-912.0K | — | ||
| Q2 24 | $2.0M | — |
| Q1 26 | 58.3% | — | ||
| Q4 25 | 68.2% | — | ||
| Q3 25 | 62.6% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 59.9% | — | ||
| Q4 24 | 70.8% | — | ||
| Q3 24 | 64.5% | — | ||
| Q2 24 | 62.6% | — |
| Q1 26 | 17.3% | — | ||
| Q4 25 | 10.6% | — | ||
| Q3 25 | -12.4% | — | ||
| Q2 25 | -7.7% | — | ||
| Q1 25 | -18.6% | 70.2% | ||
| Q4 24 | 17.3% | -60.4% | ||
| Q3 24 | -1.9% | — | ||
| Q2 24 | -5.9% | — |
| Q1 26 | -20.0% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -9.5% | — | ||
| Q2 25 | -7.3% | — | ||
| Q1 25 | -14.9% | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q3 24 | -1.3% | — | ||
| Q2 24 | 2.9% | — |
| Q1 26 | $-0.27 | — | ||
| Q4 25 | $0.14 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $-0.20 | $1.90 | ||
| Q4 24 | $0.26 | $-0.15 | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.9M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $251.0M | $350.1M |
| Total Assets | $659.4M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.9M | — | ||
| Q4 25 | $145.5M | — | ||
| Q3 25 | $136.5M | — | ||
| Q2 25 | $90.5M | — | ||
| Q1 25 | $101.8M | $274.8M | ||
| Q4 24 | $100.5M | $128.0M | ||
| Q3 24 | $78.9M | — | ||
| Q2 24 | $73.5M | — |
| Q1 26 | $251.0M | — | ||
| Q4 25 | $262.6M | — | ||
| Q3 25 | $245.1M | — | ||
| Q2 25 | $243.3M | — | ||
| Q1 25 | $275.6M | $350.1M | ||
| Q4 24 | $277.3M | $229.0M | ||
| Q3 24 | $263.2M | — | ||
| Q2 24 | $282.7M | — |
| Q1 26 | $659.4M | — | ||
| Q4 25 | $680.2M | — | ||
| Q3 25 | $676.2M | — | ||
| Q2 25 | $675.2M | — | ||
| Q1 25 | $668.6M | $406.9M | ||
| Q4 24 | $739.5M | $271.6M | ||
| Q3 24 | $689.1M | — | ||
| Q2 24 | $673.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.3M | $131.8M |
| Free Cash FlowOCF − Capex | $10.7M | $131.7M |
| FCF MarginFCF / Revenue | 17.1% | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $63.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $17.3M | — | ||
| Q4 25 | $18.2M | — | ||
| Q3 25 | $32.4M | — | ||
| Q2 25 | $14.9M | — | ||
| Q1 25 | $15.6M | $131.8M | ||
| Q4 24 | $18.0M | $-23.2M | ||
| Q3 24 | $19.1M | — | ||
| Q2 24 | $11.9M | — |
| Q1 26 | $10.7M | — | ||
| Q4 25 | $11.3M | — | ||
| Q3 25 | $27.7M | — | ||
| Q2 25 | $13.6M | — | ||
| Q1 25 | $14.2M | $131.7M | ||
| Q4 24 | $13.7M | $-23.2M | ||
| Q3 24 | $7.4M | — | ||
| Q2 24 | $11.2M | — |
| Q1 26 | 17.1% | — | ||
| Q4 25 | 14.1% | — | ||
| Q3 25 | 40.8% | — | ||
| Q2 25 | 19.1% | — | ||
| Q1 25 | 22.2% | 83.0% | ||
| Q4 24 | 16.1% | -102.7% | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 16.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | — | ||
| Q3 25 | 6.9% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 2.3% | 0.1% | ||
| Q4 24 | 5.1% | 0.2% | ||
| Q3 24 | 16.3% | — | ||
| Q2 24 | 1.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
